Daejeon, South Korea

Sun Young Koo


 

Average Co-Inventor Count = 8.9

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2012-2021

Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: The Innovations of Sun Young Koo

Introduction

Sun Young Koo is a notable inventor based in Daejeon, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that inhibit necrosis. With a total of seven patents to his name, Koo's work has the potential to impact the treatment of various necrosis-associated diseases.

Latest Patents

Koo's latest patents include an indole compound as an inhibitor of necrosis. This invention relates to a specific indole compound represented by a unique formula, which serves as a pharmaceutically acceptable salt or isomer. The composition is designed for the prevention or treatment of necrosis and associated diseases. Another significant patent is for an indole amide compound, which also acts as an inhibitor of necrosis. Similar to the previous patent, this invention includes a composition for treatment and a method for preparing it, emphasizing the active ingredient's role in combating necrosis.

Career Highlights

Throughout his career, Sun Young Koo has worked with prominent companies such as LG Life Sciences and LG Chem. His experience in these organizations has allowed him to refine his expertise in pharmaceutical innovations and contribute to groundbreaking research.

Collaborations

Koo has collaborated with several professionals in his field, including Soon Ha Kim and Hyoung Jin Kim. These partnerships have likely enhanced his research and development efforts, leading to the successful creation of his patented compounds.

Conclusion

Sun Young Koo's contributions to the field of pharmaceuticals through his innovative patents demonstrate his commitment to advancing medical science. His work in developing compounds that inhibit necrosis showcases the potential for significant advancements in treatment options for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…